Go Pro
→ Your $29.97 book is free today (From Profits Run) (Ad)tc pixel Free EFTR Stock Alerts

eFFECTOR Therapeutics (EFTR) Competitors

eFFECTOR Therapeutics logo
$0.0006 0.00 (0.00%)
As of 07/10/2026
Compare

EFTR vs. NAVB, GNCA, PXMD, ARDS, and GNCAQ

Should you buy eFFECTOR Therapeutics stock or one of its competitors? MarketBeat compares eFFECTOR Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with eFFECTOR Therapeutics include Navidea Biopharmaceuticals (NAVB), Genocea Biosciences (GNCA), PaxMedica (PXMD), Aridis Pharmaceuticals (ARDS), and Genocea Biosciences (GNCAQ). These companies are all part of the "pharmaceutical products" industry.

How does eFFECTOR Therapeutics compare to Navidea Biopharmaceuticals?

eFFECTOR Therapeutics (NASDAQ:EFTR) and Navidea Biopharmaceuticals (NYSE:NAVB) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, dividends, institutional ownership, earnings, valuation, risk, media sentiment and analyst recommendations.

eFFECTOR Therapeutics has a beta of 2.38, meaning that its share price is 138% more volatile than the broader market. Comparatively, Navidea Biopharmaceuticals has a beta of 1.76, meaning that its share price is 76% more volatile than the broader market.

Navidea Biopharmaceuticals has higher revenue and earnings than eFFECTOR Therapeutics. eFFECTOR Therapeutics is trading at a lower price-to-earnings ratio than Navidea Biopharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
eFFECTOR TherapeuticsN/AN/A-$35.81M-$13.08N/A
Navidea Biopharmaceuticals$8.13K0.00-$15.18M-$0.21N/A

Company Net Margins Return on Equity Return on Assets
eFFECTOR TherapeuticsN/A N/A N/A
Navidea Biopharmaceuticals N/A N/A N/A

57.7% of eFFECTOR Therapeutics shares are owned by institutional investors. Comparatively, 0.0% of Navidea Biopharmaceuticals shares are owned by institutional investors. 4.7% of eFFECTOR Therapeutics shares are owned by insiders. Comparatively, 43.7% of Navidea Biopharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

In the previous week, eFFECTOR Therapeutics' average media sentiment score of 0.00 equaled Navidea Biopharmaceuticals'average media sentiment score.

Company Overall Sentiment
eFFECTOR Therapeutics Neutral
Navidea Biopharmaceuticals Neutral

Summary

Navidea Biopharmaceuticals beats eFFECTOR Therapeutics on 4 of the 7 factors compared between the two stocks.

How does eFFECTOR Therapeutics compare to Genocea Biosciences?

eFFECTOR Therapeutics (NASDAQ:EFTR) and Genocea Biosciences (NASDAQ:GNCA) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, analyst recommendations, earnings, media sentiment, institutional ownership, valuation, profitability and risk.

57.7% of eFFECTOR Therapeutics shares are owned by institutional investors. Comparatively, 0.6% of Genocea Biosciences shares are owned by institutional investors. 4.7% of eFFECTOR Therapeutics shares are owned by insiders. Comparatively, 1.6% of Genocea Biosciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

eFFECTOR Therapeutics has a beta of 2.38, indicating that its share price is 138% more volatile than the broader market. Comparatively, Genocea Biosciences has a beta of 1.61, indicating that its share price is 61% more volatile than the broader market.

eFFECTOR Therapeutics' return on equity of 0.00% beat Genocea Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
eFFECTOR TherapeuticsN/A N/A N/A
Genocea Biosciences N/A -182.88%-62.76%

In the previous week, eFFECTOR Therapeutics' average media sentiment score of 0.00 equaled Genocea Biosciences'average media sentiment score.

Company Overall Sentiment
eFFECTOR Therapeutics Neutral
Genocea Biosciences Neutral

Genocea Biosciences has higher revenue and earnings than eFFECTOR Therapeutics. eFFECTOR Therapeutics is trading at a lower price-to-earnings ratio than Genocea Biosciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
eFFECTOR TherapeuticsN/AN/A-$35.81M-$13.08N/A
Genocea Biosciences$1.91M0.00-$33.20M-$0.61N/A

Summary

eFFECTOR Therapeutics beats Genocea Biosciences on 6 of the 9 factors compared between the two stocks.

How does eFFECTOR Therapeutics compare to PaxMedica?

eFFECTOR Therapeutics (NASDAQ:EFTR) and PaxMedica (NASDAQ:PXMD) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their media sentiment, risk, earnings, profitability, institutional ownership, dividends, analyst recommendations and valuation.

PaxMedica is trading at a lower price-to-earnings ratio than eFFECTOR Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
eFFECTOR TherapeuticsN/AN/A-$35.81M-$13.08N/A
PaxMedicaN/AN/A-$18.29M-$6.09N/A

eFFECTOR Therapeutics has a beta of 2.38, suggesting that its stock price is 138% more volatile than the broader market. Comparatively, PaxMedica has a beta of -0.99, suggesting that its stock price is 199% less volatile than the broader market.

57.7% of eFFECTOR Therapeutics shares are held by institutional investors. Comparatively, 4.9% of PaxMedica shares are held by institutional investors. 4.7% of eFFECTOR Therapeutics shares are held by company insiders. Comparatively, 1.0% of PaxMedica shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

eFFECTOR Therapeutics' return on equity of 0.00% beat PaxMedica's return on equity.

Company Net Margins Return on Equity Return on Assets
eFFECTOR TherapeuticsN/A N/A N/A
PaxMedica N/A -3,167.89%-560.35%

In the previous week, eFFECTOR Therapeutics' average media sentiment score of 0.00 equaled PaxMedica'saverage media sentiment score.

Company Overall Sentiment
eFFECTOR Therapeutics Neutral
PaxMedica Neutral

Summary

eFFECTOR Therapeutics beats PaxMedica on 6 of the 8 factors compared between the two stocks.

How does eFFECTOR Therapeutics compare to Aridis Pharmaceuticals?

Aridis Pharmaceuticals (NASDAQ:ARDS) and eFFECTOR Therapeutics (NASDAQ:EFTR) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, analyst recommendations, media sentiment, earnings, institutional ownership, dividends, valuation and risk.

In the previous week, Aridis Pharmaceuticals' average media sentiment score of 0.00 equaled eFFECTOR Therapeutics'average media sentiment score.

Company Overall Sentiment
Aridis Pharmaceuticals Neutral
eFFECTOR Therapeutics Neutral

9.6% of Aridis Pharmaceuticals shares are owned by institutional investors. Comparatively, 57.7% of eFFECTOR Therapeutics shares are owned by institutional investors. 5.5% of Aridis Pharmaceuticals shares are owned by company insiders. Comparatively, 4.7% of eFFECTOR Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

eFFECTOR Therapeutics is trading at a lower price-to-earnings ratio than Aridis Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Aridis PharmaceuticalsN/AN/A-$30.37M$0.310.00
eFFECTOR TherapeuticsN/AN/A-$35.81M-$13.08N/A

Aridis Pharmaceuticals has a beta of 47.59, indicating that its share price is 4,659% more volatile than the broader market. Comparatively, eFFECTOR Therapeutics has a beta of 2.38, indicating that its share price is 138% more volatile than the broader market.

Company Net Margins Return on Equity Return on Assets
Aridis PharmaceuticalsN/A N/A N/A
eFFECTOR Therapeutics N/A N/A N/A

Summary

Aridis Pharmaceuticals beats eFFECTOR Therapeutics on 5 of the 6 factors compared between the two stocks.

How does eFFECTOR Therapeutics compare to Genocea Biosciences?

eFFECTOR Therapeutics (NASDAQ:EFTR) and Genocea Biosciences (NASDAQ:GNCAQ) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, analyst recommendations, valuation, media sentiment, institutional ownership, risk, earnings and dividends.

Company Net Margins Return on Equity Return on Assets
eFFECTOR TherapeuticsN/A N/A N/A
Genocea Biosciences N/A N/A N/A

eFFECTOR Therapeutics has a beta of 2.38, suggesting that its share price is 138% more volatile than the broader market. Comparatively, Genocea Biosciences has a beta of 2.44, suggesting that its share price is 144% more volatile than the broader market.

57.7% of eFFECTOR Therapeutics shares are owned by institutional investors. 4.7% of eFFECTOR Therapeutics shares are owned by insiders. Comparatively, 1.6% of Genocea Biosciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
eFFECTOR TherapeuticsN/AN/A-$35.81M-$13.08N/A
Genocea BiosciencesN/AN/AN/AN/AN/A

In the previous week, eFFECTOR Therapeutics' average media sentiment score of 0.00 equaled Genocea Biosciences'average media sentiment score.

Company Overall Sentiment
eFFECTOR Therapeutics Neutral
Genocea Biosciences Neutral

Summary

eFFECTOR Therapeutics beats Genocea Biosciences on 3 of the 4 factors compared between the two stocks.

Get eFFECTOR Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for EFTR and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding EFTR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

EFTR vs. The Competition

Export
MetriceFFECTOR TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$3K$971.70M$7.14B$12.64B
Dividend YieldN/A4.84%2.68%7.83%
P/E Ratio0.001.6427.4224.58
Price / SalesN/A118.20593.42122.69
Price / CashN/A20.0649.3460.04
Price / Book0.008.4610.886.38
Net Income-$35.81M-$2.88M$3.59B$331.87M
7 Day PerformanceN/A-0.89%-0.26%0.37%
1 Month PerformanceN/A2.83%4.52%0.53%
1 Year PerformanceN/A43.51%29.17%21.96%

eFFECTOR Therapeutics Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
EFTR
eFFECTOR Therapeutics
N/A$0.00
flat		N/AN/A$3KN/AN/A10
NAVB
Navidea Biopharmaceuticals
N/AN/AN/AN/A$10K$8.13KN/A10
GNCA
Genocea Biosciences
N/AN/AN/AN/A$6K$1.91MN/A70
PXMD
PaxMedica
N/A$0.00
flat		N/A+600.0%$6KN/AN/A2
ARDS
Aridis Pharmaceuticals
N/AN/AN/AN/A$5KN/A0.0030

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:EFTR) was last updated on 7/11/2026 by MarketBeat.com Staff.
From Our Partners
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
The $15 Gold Fund That Pays Up to $1,152/Month
Gold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...
Investors Alley | Sponsoredtc pixel
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel
Do NOT Buy SpaceX – Do This Instead
SpaceX just went public - and Whitney Tilson, Harvard MBA and 30-year Wall Street veteran, says buying in coul...
Stansberry Research | Sponsoredtc pixel
Your $29.97 book is free today
Why Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...
Profits Run | Sponsoredtc pixel
SPCX Warning - and Worst News for Stocks in 50 Years
Goldman Sachs and Morgan Stanley are now predicting what could be the worst news for the U.S. stock market in ...
TradeSmith | Sponsoredtc pixel
CODE RED: AI Meltdown Imminent?
After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...
Paradigm Press | Sponsoredtc pixel
Better than SpaceX? Grab this ticker instead.
Larry Benedict generated $274 million for his clients by finding the trades most investors missed. Now he says...
Brownstone Research | Sponsoredtc pixel